Mike,
I honestly don't think any of your 1,2,3 points would have made a difference. The hit pieces would have still rolled out and spoofing would have still occurred. Anyone with an ounce of intelligence knew the NYAS presentation was good news.
As further proof of this, the JAMA article should have erased all doubt in anyone's mind about the success of the trial. All press since has been 99% positive save a few disgruntled MDs whose incomes are somehow tied to NVCR. Yet, the stock price has since gone down. Never really seen that happen before.
While LP is far from perfect, if someone is stacking the deck against you, you're not winning the hand. It is clear to me that forces are in play to undermine the credibility of this company. That all ends when the company hits its final milestones and starts generating serious revenue, but until then it will be a rough ride.
And by the way, continually posting on a message board that "management is incompetent" further serves to strengthen the overall message which undermines this stock. It is 100% your right to do so, but kinda seems like cutting off your nose to spite your face, eh?
--edit--
The one thing I will agree with you on is that the delays in hitting milestones have hurt the stock... A LOT. It's been the story of NW's life. Trial delayed. SAP delayed. TLD delayed. Journal delayed. That hurts, but from an operational and capital standpoint, I just don't think little NW had the resources to do it any faster. And while all of those items I mentioned were delayed... at the end of the day little NW did deliver. I am sure it will be the case with MIA and MHRA. Delayed but ultimately delivered.
